Reactome | CALCR binds erenumab

CALCR binds erenumab

Stable Identifier

R-HSA-9702818

Type

Reaction [binding]

Species

Homo sapiens

Compartment

extracellular region, plasma membrane

ReviewStatus

5/5

Locations in the PathwayBrowser

Expand all

General

SBML | | PDF

SVG | | PPTX | SBGN

Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout

Therapeutic agents that block the calcitonin gene-related peptide (CALCA, CGRP) signaling pathway are efficacious for both acute migraine treatment and migraine prevention. Erenumab (AMG 334) is a fully human monoclonal antibody against the CGRP receptor (CALCR) that competes with CALCA binding to human CALCR, inhibiting CALCA-stimulated cAMP production (Shi et al. 2016). In studies of efficacy of erenumab in patients with episodic migraine, it provided sustained efficacy in episodic migraine with good tolerability (Goadsby et al. 2020, Broessner et al. 2020).

Literature References

PubMed ID	Title	Journal	Year
32851644	The Spectrum of Response to Erenumab in Patients With Episodic Migraine and Subgroup Analysis of Patients Achieving ≥50%, ≥75%, and 100% Response Hallström, Y, Bonner, JH, Reuter, U, Picard, H, Broessner, G, Mikol, DD, Dodick, DW, Klatt, J, Lenz, RA, Zhang, F	Headache	2020
32636324	One-year sustained efficacy of erenumab in episodic migraine: Results of the STRIVE study Hallström, Y, Goadsby, PJ, Bonner, JH, Reuter, U, Picard, H, Broessner, G, Mikol, DD, Lenz, RA, Klatt, J, Wright, IK, Chou, DE, Zhang, F	Neurology	2020
26559125	Pharmacologic Characterization of AMG 334, a Potent and Selective Human Monoclonal Antibody against the Calcitonin Gene-Related Peptide Receptor Lehto, SG, Xu, C, Sun, H, Zhang, J, Smith, BP, Immke, DC, Wild, KD, Zhu, DX, Shi, L	J. Pharmacol. Exp. Ther.	2016